Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
HPTN 102: LEN in Women (HIV Prevention Medication)
Phase 2
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
Pursuing Optimal Organisms in People with Stones
The incidence of kidney stone disease, especially among children, has risen rapidly. The goal of this study is to determine how what you eat and drink (your diet), antibiotics you take, and the bacteria that live in your gut (microbiome) contribute to developing kidney stones.
HIV Prevention Research Division: Generic Interest Form
The purpose of this study is to determine if you may be eligible to participate in one of ourcurrent research studies being conducted at the University of Pennsylvania. The purposes ofthese studies are to test different methods that might protect people against viruses thatcause transmittable infections or to develop better ways to treat these infections. Some ofthe viruses these methods will test to prevent are HIV the virus that causes AIDS and HPV(Human Papilloma Virus) that can cause penile, throat and cervical cancer.
Open label comparison of injectable buprenorphine (CAM2038 Brixadi ) and naltrexone (Vivitrol ) for opioid use disorder
Phase 2
Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or reports of two or more periods of 3 days of opioid use in the 3rd (last) month of treatment, is late for more than 2 weeks for XRNTX or XRBUP treatment, or drops out of treatment prior to the 3rd injection, will be classified as treatment failures; otherwise, they will be classified as a treatment success. Test an integrated brain-behavior model of relapse vulnerability in OUD; ASI composite scores; effects of Group and neural change variables on other substance use outcomes
Effects of Phloroglucinol vs. Placebo on IBS-D (Irritable Bowel Syndrome- Predominant Diarrhea)
Phase 2
To evaluate the clinical response of multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency (as a composite responder) in subjects with IBS-D (Irritable Bowel Syndrome Prominently Diarrhea) over 12 weeks of treatment and the safety and tolerability of multiple dose strengths of CIN-103 relative to placebo in subjects with IBS-D over 12 weeks of treatment. The population is adult subjects 18 years and older who meet Rome IV Criteria for IBS-D and do not have evidence of other gastrointestinal diseases.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
